Coronavirus disease 2019 (COVID-19) caused by the novel human coronavirus, SARS-CoV-2 is currently a major threat to public health in worldwide. To deal with the needs of vaccine, we developed an alternative DNA vaccine candidates against SARS-CoV-2, based on full-length of spike protein (S) and a truncated SΔCD, SΔTM, S1 subunit glycoprotein. Following vaccination of mice, we measured T cell response and antigen-specific functional antibodies which neutralize the viral infection with SARS-CoV-2. All groups of DNA vaccine candidates induced not only humoral immune responses such as total IgG, and neutralization antibodies, but also cell-mediated immune responses as multiple cytokines. Especially, DNA vaccine containing the full-length of S significantly enhanced immune response rather than others. We selected the S as valuable antigen and evaluated to determine the dosage of S antigen and vaccination schedule. Regardless of the dose of antigen, all groups showed an induced immune response compared to the control group, immunized with pVax1. But the 50μg inoculated group showed higher neutralizing antibody titer than the 20μg and 5μg group, and significantly increased up to three times of vaccination. These findings showed that a potential vaccine candidate using DNA platform for prevention of SARS-CoV-2 infection.